Company Overview

MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on developing immunology therapies for inflammatory diseases. The company’s lead asset is sonelokimab, a tri-specific Nanobody designed to target interleukin-17A and interleukin-17F pathways associated with chronic inflammatory disorders. MoonLake operates within the biotechnology and biopharmaceutical industries, with a primary emphasis on immunology, dermatology, rheumatology, and related inflammatory conditions.

The company’s core value proposition is centered on the potential differentiation of its Nanobody platform, which is designed to offer tissue penetration, molecular specificity, and dosing flexibility compared with conventional monoclonal antibody therapies. MoonLake has concentrated its development efforts on diseases such as hidradenitis suppurativa, psoriatic arthritis, and other IL-17-mediated conditions. The company evolved from a privately held biotechnology venture into a publicly traded entity through a business combination with Helix Acquisition Corp., after which it began trading on Nasdaq under the ticker MLTX.

Business Operations

MoonLake primarily operates as a single clinical-stage biotechnology business focused on the research, development, and potential commercialization of immunotherapies. Its principal business activity is advancing sonelokimab through clinical development programs, including late-stage and mid-stage trials targeting inflammatory diseases with significant unmet medical need. As of publicly available filings and company disclosures, the company does not generate recurring commercial product revenue and relies primarily on financing activities and capital markets funding to support operations.

The company maintains research, clinical development, and corporate operations across multiple jurisdictions, with strategic activities spanning Europe and the United States. MoonLake’s technology portfolio is built around Nanobody-based biologics originally derived from technology licensed through partnerships associated with the VIB and Ablynx/Sanofi scientific ecosystem. The company manages clinical trial networks, regulatory engagement, and external manufacturing relationships through a combination of internal leadership and specialized third-party partners.

Strategic Position & Investments

MoonLake’s strategic direction is focused on positioning sonelokimab as a potentially differentiated therapy within the competitive IL-17 inhibitor market. The company has emphasized expanding clinical indications, accelerating late-stage development programs, and pursuing regulatory pathways in large inflammatory disease markets. Strategic execution has included investment in global clinical trial infrastructure, manufacturing readiness, and commercial planning capabilities intended to support future product launches if regulatory approvals are achieved.

The company has also pursued growth through capital raises and public market financing to support broader development activities. MoonLake’s positioning in the immunology sector is closely tied to the broader trend toward precision biologics and next-generation cytokine-targeting therapies. Public disclosures indicate continued investment in clinical expansion opportunities for sonelokimab, particularly in diseases where existing biologics may have limitations related to efficacy, dosing convenience, or tissue penetration.

Geographic Footprint

MoonLake Immunotherapeutics is headquartered in Zug, Switzerland, with operational activities extending into the United States and other international markets through clinical development and research partnerships. The company conducts multinational clinical trials across North America, Europe, and additional regions where regulatory and patient recruitment infrastructure support immunology studies.

Its global footprint is primarily driven by clinical operations, regulatory engagement, and investor market access rather than large-scale commercial manufacturing or sales infrastructure. MoonLake’s Nasdaq listing has strengthened its access to U.S. capital markets while maintaining a European operational base, reflecting a cross-border biotechnology operating model commonly used by growth-stage biopharmaceutical companies.

Leadership & Governance

MoonLake’s leadership team combines biotechnology, clinical development, immunology, and capital markets experience. The company has emphasized a strategy focused on disciplined clinical execution, targeted portfolio development, and advancing differentiated immunology therapies in high-value disease categories. Governance oversight is structured through a board and executive team with experience across pharmaceutical development and biotechnology commercialization.

Key executives include:

• Jorge Santos da Silva – Chief Executive Officer and Co-Founder
• Mark Iwicki – Chairman of the Board
• Andrew Sandler – Chief Financial Officer
• Tomasz Kula – Chief Medical Officer

Public company governance practices are aligned with Nasdaq-listed biotechnology standards, including oversight related to clinical development, financial reporting, and regulatory compliance through board-level governance structures and committee frameworks.